Literature DB >> 28622628

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Jeong A Park1, Nai-Kong V Cheung2.   

Abstract

Immune checkpoint inhibitors (ICI) have shown great promise in a wide spectrum of adult solid and hematological malignancies, achieving objective tumor responses and prolonging survival. However, there is limited clinical success amongst pediatric patients. In this review, we summarize the current understanding of ICI and present an up-to-date overview of recent and ongoing clinical trials of ICI in pediatric malignancies. In addition, we will discuss immunologic and clinical difficulties in this young population, as well as future prospects for combination of ICI with other immune-based and conventional treatments.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cytotoxic T lymphocyte antigen-4 (CTLA-4); Immune checkpoint inhibitor; Immunotherapy; Programmed death receptor-1 (PD-1); Programmed death-ligand 1 (PD-L1)

Mesh：

Substances：

Year:  2017        PMID： 28622628      PMCID： PMC5524462          DOI： 10.1016/j.ctrv.2017.05.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  190 in total

1.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

2.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

Authors:  S Wilgenhof; B Neyns
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

3.  Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patients.

Authors:  Zhou Bin; Zhang Guangbo; Ge Yan; Zhou Huan; Lv Desheng; Zhang Xueguang
Journal:  J Surg Res       Date:  2014-01-24       Impact factor: 2.192

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

6.  LAG-3, a novel lymphocyte activation gene closely related to CD4.

Authors:  F Triebel; S Jitsukawa; E Baixeras; S Roman-Roman; C Genevee; E Viegas-Pequignot; T Hercend
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

Review 7.  Understanding the Mysterious M2 Macrophage through Activation Markers and Effector Mechanisms.

Authors:  Tamás Rőszer
Journal:  Mediators Inflamm       Date:  2015-05-18       Impact factor: 4.711

8.  Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.

Authors:  Thomas Köhnke; Christina Krupka; Johanna Tischer; Thomas Knösel; Marion Subklewe
Journal:  J Hematol Oncol       Date:  2015-10-08       Impact factor: 17.388

9.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

Review 10.  Tremelimumab: research and clinical development.

Authors:  Begoña Comin-Anduix; Helena Escuin-Ordinas; Francisco Javier Ibarrondo
Journal:  Onco Targets Ther       Date:  2016-03-23       Impact factor: 4.147
View more
  26 in total

1.  Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment.

Authors:  Eric J Chow; Kasey J Leger; Neel S Bhatt; Daniel A Mulrooney; Colin J Ross; Sanjeev Aggarwal; Neha Bansal; Matthew J Ehrhardt; Saro H Armenian; Jessica M Scott; Borah Hong
Journal:  Cardiovasc Res       Date:  2019-04-15       Impact factor: 10.787

Review 2.  The role of anti-tumor immunity of focused ultrasound for the malignancies: depended on the different ablation categories.

Authors:  Luping Zhang; Chao Yang; Yixing Gao; Jinyun Chen; Wenzhi Chen
Journal:  Int J Clin Oncol       Date:  2022-08-09       Impact factor: 3.850

Review 3.  Immune profiling of pediatric solid tumors.

Authors:  Rachael L Terry; Deborah Meyran; David S Ziegler; Michelle Haber; Paul G Ekert; Joseph A Trapani; Paul J Neeson
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 4.  Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018.

Authors:  Tanvir F Kabir; Aman Chauhan; Lowell Anthony; Gerhard C Hildebrandt
Journal:  Ochsner J       Date:  2018

Review 5.  Nanotechnology-based immunotherapies to combat cancer metastasis.

Authors:  Yuping Zhao; Muhammad Bilal; Maimoona Qindeel; Muhammad Imran Khan; Kuldeep Dhama; Hafiz M N Iqbal
Journal:  Mol Biol Rep       Date:  2021-08-23       Impact factor: 2.316

6.  High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy.

Authors:  Avinash Eranki; Priya Srinivasan; Mario Ries; AeRang Kim; Christopher A Lazarski; Christopher T Rossi; Tatiana D Khokhlova; Emmanuel Wilson; Susan M Knoblach; Karun V Sharma; Bradford J Wood; Chrit Moonen; Anthony D Sandler; Peter C W Kim
Journal:  Clin Cancer Res       Date:  2019-10-15       Impact factor: 13.801

7.  Antigen cross-presentation in young tumor-bearing hosts promotes CD8+ T cell terminal differentiation.

Authors:  Ardiana Moustaki; Jeremy Chase Crawford; Shanta Alli; Yiping Fan; Shannon Boi; Anthony E Zamora; Natalie M N McDonald; Gang Wu; Joy Nakitandwe; Scott Newman; Scott Foy; Antonina Silkov; Paul G Thomas; Alberto Pappo; Michael A Dyer; Elizabeth Stewart; Sara Federico; Ben Youngblood
Journal:  Sci Immunol       Date:  2022-02-04

Review 8.  Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.

Authors:  Michael M Boyiadzis; Madhav V Dhodapkar; Renier J Brentjens; James N Kochenderfer; Sattva S Neelapu; Marcela V Maus; David L Porter; David G Maloney; Stephan A Grupp; Crystal L Mackall; Carl H June; Michael R Bishop
Journal:  J Immunother Cancer       Date:  2018-12-04       Impact factor: 13.751

9.  Synthetic bacterial vesicles combined with tumour extracellular vesicles as cancer immunotherapy.

Authors:  Kyong-Su Park; Kristina Svennerholm; Rossella Crescitelli; Cecilia Lässer; Inta Gribonika; Jan Lötvall
Journal:  J Extracell Vesicles       Date:  2021-07-03

10.  Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.

Authors:  Riyue Bao; Stefani Spranger; Kyle Hernandez; Yuanyuan Zha; Peter Pytel; Jason J Luke; Thomas F Gajewski; Samuel L Volchenboum; Susan L Cohn; Ami V Desai
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.